Septerna, Inc. Common Stock (SEPN) - Total Assets
Based on the latest financial reports, Septerna, Inc. Common Stock (SEPN) holds total assets worth $606.65 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Septerna, Inc. Common Stock book value and equity for net asset value and shareholders' equity analysis.
Septerna, Inc. Common Stock - Total Assets Trend (2022–2024)
This chart illustrates how Septerna, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data.
Septerna, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Septerna, Inc. Common Stock's total assets of $606.65 Million consist of 78.2% current assets and 21.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 52.2% |
| Accounts Receivable | $1.12 Million | 0.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2024)
This chart illustrates how Septerna, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SEPN market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Septerna, Inc. Common Stock's current assets represent 78.2% of total assets in 2024, a decrease from 88.3% in 2022.
- Cash Position: Cash and equivalents constituted 52.2% of total assets in 2024, down from 84.7% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 0.3% of total assets.
Septerna, Inc. Common Stock Competitors by Total Assets
Key competitors of Septerna, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Septerna, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.53 | 10.08 | 16.30 |
| Quick Ratio | 6.53 | 10.08 | 16.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $416.40 Million | $120.18 Million | $105.76 Million |
Septerna, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Septerna, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.17 |
| Latest Market Cap to Assets Ratio | 2.32 |
| Asset Growth Rate (YoY) | 248.9% |
| Total Assets | $456.55 Million |
| Market Capitalization | $1.06 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Septerna, Inc. Common Stock's assets at a significant premium (2.32x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Septerna, Inc. Common Stock's assets grew by 248.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Septerna, Inc. Common Stock (2022–2024)
The table below shows the annual total assets of Septerna, Inc. Common Stock from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $456.55 Million | +248.87% |
| 2023-12-31 | $130.87 Million | +262.32% |
| 2022-12-31 | $36.12 Million | -- |
About Septerna, Inc. Common Stock
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 … Read more